Literature DB >> 31930521

Th2A and Th17 cell frequencies and regulatory markers as follow-up biomarker candidates for successful multifood oral immunotherapy.

Sonia Luce1, Sharon Chinthrajah2,3, Shu-Chen Lyu2,3, Kari C Nadeau2,3, Laurent Mascarell1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31930521      PMCID： PMC8164780          DOI： 10.1111/all.14180

Source DB:  PubMed          Journal:  Allergy        ISSN： 0105-4538            Impact factor:   13.146


× No keyword cloud information.
  9 in total

1.  Initial immunological changes as predictors for house dust mite immunotherapy response.

Authors:  E Gómez; T D Fernández; I Doña; C Rondon; P Campo; F Gomez; M Salas; M Gonzalez; J R Perkins; F Palomares; M Blanca; M J Torres; C Mayorga
Journal:  Clin Exp Allergy       Date:  2015-10       Impact factor: 5.018

2.  Allergen-specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy.

Authors:  M Bonvalet; H Moussu; E Wambre; C Ricarte; S Horiot; A-C Rimaniol; W W Kwok; F Horak; O de Beaumont; V Baron-Bodo; P Moingeon
Journal:  Clin Exp Allergy       Date:  2012-12       Impact factor: 5.018

3.  Stabilin-1/CLEVER-1, a type 2 macrophage marker, is an adhesion and scavenging molecule on human placental macrophages.

Authors:  Senthil Palani; Mikael Maksimow; Mari Miiluniemi; Kaisa Auvinen; Sirpa Jalkanen; Marko Salmi
Journal:  Eur J Immunol       Date:  2011-06-01       Impact factor: 5.532

Review 4.  Advances and highlights in allergen immunotherapy: On the way to sustained clinical and immunologic tolerance.

Authors:  Margot Berings; Cagatay Karaaslan; Can Altunbulakli; Philippe Gevaert; Mübeccel Akdis; Claus Bachert; Cezmi A Akdis
Journal:  J Allergy Clin Immunol       Date:  2017-09-20       Impact factor: 10.793

5.  Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy.

Authors:  Claire Gueguen; Julien Bouley; Hélène Moussu; Sonia Luce; Magalie Duchateau; Julia Chamot-Rooke; Marc Pallardy; Vincent Lombardi; Emmanuel Nony; Véronique Baron-Bodo; Laurent Mascarell; Philippe Moingeon
Journal:  J Allergy Clin Immunol       Date:  2015-10-29       Impact factor: 10.793

6.  A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy.

Authors:  Aline Zimmer; Julien Bouley; Maxime Le Mignon; Elodie Pliquet; Stéphane Horiot; Mathilde Turfkruyer; Véronique Baron-Bodo; Friedrich Horak; Emmanuel Nony; Anne Louise; Hélène Moussu; Laurent Mascarell; Philippe Moingeon
Journal:  J Allergy Clin Immunol       Date:  2012-04       Impact factor: 14.290

7.  A Phase 2 Randomized Controlled Multisite Study Using Omalizumab-facilitated Rapid Desensitization to Test Continued vs Discontinued Dosing in Multifood Allergic Individuals.

Authors:  Sandra Andorf; Natasha Purington; Divya Kumar; Andrew Long; Katherine L O'Laughlin; Scott Sicherer; Hugh Sampson; Antonella Cianferoni; Terri Brown Whitehorn; Daniel Petroni; Melanie Makhija; Rachel G Robison; Michelle Lierl; Stephanie Logsdon; Manisha Desai; Stephen J Galli; Efren Rael; Amal Assa'ad; Sharon Chinthrajah; Jacqueline Pongracic; Jonathan M Spergel; Jonathan Tam; Stephen Tilles; Julie Wang; Kari Nadeau
Journal:  EClinicalMedicine       Date:  2019-01-21

Review 8.  The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses.

Authors:  Sayantani B Sindher; Andrew Long; Swati Acharya; Vanitha Sampath; Kari C Nadeau
Journal:  Clin Rev Allergy Immunol       Date:  2018-10       Impact factor: 8.667

9.  Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper.

Authors:  M H Shamji; J H Kappen; M Akdis; E Jensen-Jarolim; E F Knol; J Kleine-Tebbe; B Bohle; A M Chaker; S J Till; R Valenta; L K Poulsen; M A Calderon; P Demoly; O Pfaar; L Jacobsen; S R Durham; C B Schmidt-Weber
Journal:  Allergy       Date:  2017-04-06       Impact factor: 13.146
  9 in total
  6 in total

Review 1.  Advances and highlights in biomarkers of allergic diseases.

Authors:  Ismail Ogulur; Yagiz Pat; Ozge Ardicli; Elena Barletta; Lacin Cevhertas; Ruben Fernandez-Santamaria; Mengting Huang; Manal Bel Imam; Jana Koch; Siyuan Ma; Debbie J Maurer; Yasutaka Mitamura; Yaqi Peng; Urszula Radzikowska; Arturo O Rinaldi; Juan Rodriguez-Coira; Pattraporn Satitsuksanoa; Stephan R Schneider; Alexandra Wallimann; Damir Zhakparov; Reihane Ziadlou; Marie-Charlotte Brüggen; Willem van de Veen; Milena Sokolowska; Katja Baerenfaller; Luo Zhang; Mubeccel Akdis; Cezmi A Akdis
Journal:  Allergy       Date:  2021-09-27       Impact factor: 14.710

2.  Peanut oral immunotherapy differentially suppresses clonally distinct subsets of T helper cells.

Authors:  Brinda Monian; Ang A Tu; Bert Ruiter; Duncan M Morgan; Patrick M Petrossian; Neal P Smith; Todd M Gierahn; Julia H Ginder; Wayne G Shreffler; J Christopher Love
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808

3.  ICS/LABA Combined With Subcutaneous Immunotherapy Modulates the Th17/Treg Imbalance in Asthmatic Children.

Authors:  Huan Dai; Rongying Zheng; Like Wang; Jinyi Wan; Yu Tong; Wei Zhao; Weixi Zhang
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

Review 4.  Th2A cells: The pathogenic players in allergic diseases.

Authors:  Ziyu Huang; Ming Chu; Xi Chen; Ziyuan Wang; Lin Jiang; Yinchao Ma; Yuedan Wang
Journal:  Front Immunol       Date:  2022-08-08       Impact factor: 8.786

Review 5.  Biomarkers in oral immunotherapy.

Authors:  Haitao Zhu; Kaifa Tang; Guoqiang Chen; Zhongwei Liu
Journal:  J Zhejiang Univ Sci B       Date:  2022 Sept 15       Impact factor: 5.552

6.  Interpreting success or failure of peanut oral immunotherapy.

Authors:  Shijie Cao; Cathryn R Nagler
Journal:  J Clin Invest       Date:  2022-01-18       Impact factor: 14.808
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.